Business Context and Reporting Period
Company: Werewolf Therapeutics, Inc. (HOWL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: An innovative biopharmaceutical company developing therapeutics to stimulate the immune system for cancer treatment. The company is currently in a strategic review process to explore alternatives to maximize stockholder value, including potential asset sales, mergers, or collaborations. It has no products approved for commercial sale.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $21.0 million | $0 | N/A |
| Net Loss | $(9.9) million | $(36.1) million | N/A |
| Operating Expenses | $27.1 million | $35.5 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $22.0 million |
| Total Debt | N/A | N/A | $0 (Fully Repaid) |
| Accumulated Deficit | N/A | N/A | $(485.3) million |
| Stockholders' Equity | N/A | N/A | $16.3 million |
Note: Revenue for the six months ended June 30, 2026, consists entirely of a $21.0 million upfront payment from an asset purchase agreement with Jazz Pharmaceuticals. The company reported a net loss of $9.9 million for the period, compared to a net loss of $36.1 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $21.0 million in collaboration revenue in Q2 2026 following the sale of the "898 Program" (JZP898) to Jazz Pharmaceuticals. No revenue was recognized in the comparable 2025 period.
- Debt Extinguishment: In May 2026, the company fully repaid its K2HV Loan Agreement ($31.4 million payment), resulting in a one-time loss on extinguishment of debt of $3.4 million. The company had $28.2 million in note payable liabilities as of December 31, 2025.
- Restructuring Costs: The company initiated a "2026 Restructuring" involving significant workforce reductions (64% in February, 36% in May). Restructuring costs of $5.7 million were recognized in the first six months of 2026, compared to none in 2025.
- Operating Expenses: Total operating expenses decreased by $8.4 million year-over-year, driven by reduced personnel and clinical trial costs due to the restructuring and strategic pivot, partially offset by increased professional fees related to the strategic review.
- Liquidity: Cash and cash equivalents decreased from $57.1 million at year-end 2025 to $22.0 million at June 30, 2026, primarily due to debt repayment and operating cash usage.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of the report. The company expects to incur substantial operating losses and negative cash flows for the foreseeable future.
- Strategic Review: The company is actively exploring strategic alternatives, including a sale of the company, business combination, or asset sales. The outcome of this review will determine future funding requirements and development plans.
- Capital Requirements: The company will need substantial additional funding to finance operations and complete the development of product candidates WTX-124 and WTX-330. There is no assurance that additional financing will be available on acceptable terms.
- Nasdaq Compliance: The company received a deficiency notice from Nasdaq regarding the minimum bid price requirement (stock closed below $1.00 for 30 consecutive days). It has until August 3, 2026, to regain compliance or risk delisting.
- Lease Termination: The company terminated its primary lease in Watertown, Massachusetts, effective July 31, 2026, paying a $2.7 million termination fee to reduce future obligations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the remaining $22.0 million cash balance to fund operations through the strategic review process and potential clinical trial completions.
- Strategic Alternatives Timeline: Monitor progress of the strategic review process and any announcements regarding asset sales, mergers, or partnerships.
- Nasdaq Listing Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by August 3, 2026, to avoid delisting.
- Restructuring Completion: Confirm the finalization of the 2026 Restructuring and the realization of expected cost savings.
- Product Development Milestones: Review updates on the Phase 1/1b trial for WTX-124 and Phase 1b/2 trial for WTX-330, expected to complete in Q4 2026.